KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vir Biotechnology (VIR) Assets Average (2019 - 2025)

Vir Biotechnology's Assets Average history spans 7 years, with the latest figure at $1.0 billion for Q4 2025.

  • For Q4 2025, Assets Average fell 30.2% year-over-year to $1.0 billion; the TTM value through Dec 2025 reached $1.0 billion, down 30.2%, while the annual FY2025 figure was $1.2 billion, 27.62% down from the prior year.
  • Assets Average for Q4 2025 was $1.0 billion at Vir Biotechnology, down from $1.1 billion in the prior quarter.
  • Across five years, Assets Average topped out at $2.8 billion in Q2 2022 and bottomed at $1.0 billion in Q4 2025.
  • The 5-year median for Assets Average is $1.7 billion (2024), against an average of $1.8 billion.
  • The largest annual shift saw Assets Average surged 151.06% in 2022 before it crashed 32.1% in 2024.
  • A 5-year view of Assets Average shows it stood at $1.6 billion in 2021, then surged by 73.74% to $2.7 billion in 2022, then fell by 27.9% to $2.0 billion in 2023, then decreased by 26.91% to $1.4 billion in 2024, then plummeted by 30.2% to $1.0 billion in 2025.
  • Per Business Quant, the three most recent readings for VIR's Assets Average are $1.0 billion (Q4 2025), $1.1 billion (Q3 2025), and $1.3 billion (Q2 2025).